Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data.
The extent of hypersalivation was evaluated in a group of 25 schizophrenic patients on clozapine. A high prevalence of the complaint was detected by a questionnaire; up to 80% of the patients complained of hypersalivation at night. Salivary flow-rate and composition was examined in 17 patients who agreed to participate and in a matched group of healthy controls. No significant differences were detected in composition or flow-rates of resting and stimulated saliva. The salivary flow-rates in the schizophrenic patients on clozapine did not correlate with the subjective complaint of hypersalivation. Because the severity and prevalence of the complaint was higher at night, a possibility of an altered circadian rhythm of salivation might be suggested in these patients.
Ben-Aryeh
H
H
Laboratory of Oral Biology, Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel.
Jungerman
T
T
Szargel
R
R
Klein
E
E
Laufer
D
D
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000378:metabolism; D012463:Saliva / Q000378:metabolism*; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D012798:Sialorrhea / Q000139:chemically induced* / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013649:Taste / Q000187:drug effects / Q000502:physiology
D014150:Antipsychotic Agents; D012964:Sodium; D003024:Clozapine; D011188:Potassium